Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14846284 | 0.90 | POLB (0.50) | MALT1LMNAPKM | |
| SCHEMBL14833075 | 0.89 | ADRB2 (0.44) | MALT1BRD4BCHECNR2DRD2 | |
| SCHEMBL7006722 | 0.88 | MALT1 (0.54) | MALT1IDO1BRD4DRD2TPSAB1 | |
| SCHEMBL20500894 | 0.86 | MALT1 (0.51) | MALT1IDO1SMN1; SMN2BRD4PDK2 | |
| SCHEMBL25974776 | 0.86 | MALT1 (0.52) | MALT1BRD4DRD2TPSAB1TPSD1 | |
| SCHEMBL8139824 | 0.85 | BRD4 (0.53) | MALT1BRD4DRD2TPSAB1TPSD1 | |
| SCHEMBL25719625 | 0.84 | GAA (0.58) | MALT1IDO1BCHECNR2PDK2 | |
| SCHEMBL14873853 | 0.84 | TPSAB1 (0.44) | MALT1BRD4DRD2TPSAB1TPSD1 | |
| SCHEMBL31655700 | 0.84 | TPSAB1 (0.54) | MALT1BRD4DRD2TPSAB1TPSD1 | |
| SCHEMBL22291518 | 0.84 | TPSAB1 (0.54) | MALT1BRD4DRD2TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
| EP-2123283-A1 | THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | MALT1 29/4885IDO1 2138/4885SMN1; SMN2 3573/4885 |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ALAD, SLC27A2, ANTXR2 | MALT1 1017/4885IDO1 3626/4885SMN1; SMN2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.